Quick Answer
Arbutus Biopharma Corp reported Net Income of -$33.50 million for fiscal year 2025.
Arbutus Biopharma Corp Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$33.50M | +52.1% |
| 2024 | -$69.92M | +4.0% |
| 2023 | -$72.85M | -4.9% |
| 2022 | -$69.46M | +8.9% |
| 2021 | -$76.25M | -19.6% |
| 2020 | -$63.74M | +58.5% |
| 2019 | -$153.72M | -169.4% |
| 2018 | -$57.06M | +32.4% |
| 2017 | -$84.41M | +78.0% |
| 2016 | -$384.16M | -512.5% |
| 2015 | -$62.72M | -61.5% |
| 2014 | -$38.84M | -176.2% |
| 2013 | -$14.06M | -147.5% |
| 2012 | $29.61M | +393.7% |
| 2011 | -$10.08M | +18.8% |
| 2010 | -$12.42M | -41.9% |
| 2009 | -$8.75M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.74M | +60.7% | -406.9% |
| June 30, 2025 | $2.52M | +112.7% | +110.3% |
| March 31, 2025 | -$24.53M | -37.2% | -24.4% |
| September 30, 2024 | -$19.72M | +1.9% | +0.4% |
| June 30, 2024 | -$19.80M | -15.8% | -10.7% |
| March 31, 2024 | -$17.88M | -9.4% | +11.1% |
| September 30, 2023 | -$20.10M | -14.4% | -17.6% |
| June 30, 2023 | -$17.09M | -20.4% | -4.6% |
- Arbutus Biopharma Corp showed an increase of +52.1% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Arbutus Biopharma Corp’s net income has declined by 282.9% (from -$8.75 million to -$33.50 million).
- The most recent figure is from Arbutus Biopharma Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: